Drug or treatment
Ivarmacitinib clinical trials
As of November 12, 2026, Find a Trial lists 4 clinical trials of Ivarmacitinib that are recruiting, in China. 1 was first registered in the last 30 days. By phase: Phase 2 (3). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 1New in 30 days
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Ivarmacitinib with Camrelizumab and Fruquintinib in advanced colorectal cancer after prior therapies | Phase 2 | Wuhan, Hubei | Recruiting | Oct 26, 2026 |
| Low-dose ATG/PTCy plus ivarmacitinib to prevent acute GVHD after haploidentical PBSC transplant from parous female donors | Phase 2 | Shanghai, Shanghai Municipality | Recruiting | May 6, 2026 |
| Camrelizumab, chemotherapy and Ivarmacitinib before surgery for resectable esophageal squamous cell carcinoma | Phase 2 | Hangzhou, China | Recruiting | Apr 1, 2026 |
| Ivarmacitinib for palmoplantar pustulosis (open-label, single-arm treatment) | — | Xi'an, Shaanxi | Recruiting | Dec 8, 2025 |
All recruiting trials (4)
-
Ivarmacitinib with Camrelizumab and Fruquintinib in advanced colorectal cancer after prior therapies
This trial tests whether combining ivarmacitinib with camrelizumab and fruquintinib can help patients with metastatic colorectal cancer who have progressed after multiple treatments.
-
Low-dose ATG/PTCy plus ivarmacitinib to prevent acute GVHD after haploidentical PBSC transplant from parous female donors
This tests whether adding the oral JAK1 inhibitor ivarmacitinib to low-dose ATG and post‑transplant cyclophosphamide can prevent acute GVHD in adults receiving haploidentical peripheral blood stem cell transplants from parous female donors.
-
Camrelizumab, chemotherapy and Ivarmacitinib before surgery for resectable esophageal squamous cell carcinoma
This trial tests whether giving camrelizumab with chemotherapy and the JAK inhibitor Ivarmacitinib before surgery can improve outcomes for patients with locally advanced esophageal squamous cell carcinoma that can be removed by operation.
-
Ivarmacitinib for palmoplantar pustulosis (open-label, single-arm treatment)
This trial will try the oral drug ivarmacitinib to see if it reduces pustules and other skin symptoms in adults with palmoplantar pustulosis who have not responded to at least one systemic therapy.
Quick answers
How many clinical trials of Ivarmacitinib are recruiting right now?
4, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.